The effect of human immunodeficiency virus on hepatitis B virus serologic status in co-infected adults

PLoS ONE

Volumn 5, Issue 1, 2010, Pages

  Landrum, Michael L ^a,b   Fieberg, Ann M ^a,c   Chun, Helen M ^d   Crum Cianflone, Nancy F ^b,d   Marconi, Vincent C ^b,g   Weintrob, Amy C ^a,e   Ganesan, Anuradha ^a,e   Barthel, Robert V ^f   Wortmann, Glenn ^e   Agan, Brian K ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b SAN ANTONIO MILITARY MEDICAL CENTER   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^e WALTER REED ARMY MEDICAL CENTER   (United States)

^f NAVAL MEDICAL CENTER PORTSMOUTH   (United States)

^g EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CHRONIC HEPATITIS; COHORT ANALYSIS; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; RETROSPECTIVE STUDY; SEROCONVERSION; SEROLOGY;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HEPATITIS B; HIV; HIV INFECTIONS; HUMANS; MALE; RETROSPECTIVE STUDIES;

HEPATITIS B VIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 77952472602     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0008687     Document Type: Article

References (33)

1. Thio CL, Seaberg EC, Skolasky R, Phair J, Visscher B, et al. (2002) HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 360: 1921-1926.
2. Soriano V, Puoti M, Peters M, Benhamou Y, Sulkowski M, et al. (2008) Care of HIV patients with chronic hepatitis B: updated recommendations from the HIVhepatitis B virus international panel. AIDS 22: 1399-1410.
3. Tedaldi E, Peters L, Neuhaus J, Puoti M, Rockstroh J, et al. (2008) Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. Clinical Infectious Diseases 47: 1468-1475.
4. Chun HM, Landrum ML (2007) Liver-related complications in HIV-infected individuals. Infect Dis Clin Practice 15: 38-48.
5. Sulkowski MS (2008) Management of hepatitic complications in HIV-infected persons. Journal of Infectious Diseases 197: s279-293.
6. The Data Collection on Adverse Events of Anti-HIV Drugs Study Group (2006) Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Archives of Internal Medicine 166: 1632-1641.
7. Centers for Disease Control and Prevention (2006) A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: Immunization of Adults. MMWR 55:1-25.
8. Landrum ML, Huppler Hullsiek K, Ganesan A, Weintrob AC, Crum-Cianflone NF, et al. (2009) Hepatitis B vaccination and risk of hepatitis B infection in HIV-infected individuals. AIDS 23: DOI 10.1097/QAD.1090-b1013e32832cd32899e.
9. Bodsworth NJ, Cooper DA, Donovan B (1991) The influence of human immunodeficiency virus type 1 infection on the development of hepatitis B virus carrier state. Journal of Infectious Diseases 163: 1138-1140.
10. Hyams KC (1995) Risks of chronicity following acute hepatitis B virus infection: a review. Clinical Infectious Diseases 20: 992-1000.
11. Panel on Antiretroviral Guidelines for Adults and Adolescents (November 3 2008) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services November 3, 2008: 1-139. Available at http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL. pdf. Accessed May 15, 2009.
12. Hammer SM, Eron JJ, Reiss P, Schooley RT, Thompson MA, et al. (2008) Antiretroviral treatment of adult HIV infection 2008 recommendations fo the International AIDS Society- USA Panel. JAMA 300: 555-570.
13. Puoti M, Torti C, Bruno R, Filice G, Carosi G (2006) Natural history of chronic hepatitis B in co-infected patients. Journal of Hepatology 44: s65-70.
14. Carr A, Cooper DA (1997) Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor. Lancet 349: 995-996.
15. Velasco M, Moran A, Tellez MJ (1999) Resolution of chronic hepatitis B after ritonavir treatment in an HIV-infected patient. New England Journal of Medicine 340: 1765-1766.
16. Nunez M, Ramos B, Diaz-Pollan B, Camino N, Martin-Carbonero L, et al. (2006) Virological outcome of chronic hepatitis B virus infection in HIVcoinfected patients receiving anti-HBV active antiretroviral therapy. AIDS Research & Human Retroviruses 22: 842-848.
17. Miailhes P, Trabaud M-A, Pradat P, Lebouche B, Chevallier M, et al. (2007) Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion.[see comment]. Clinical Infectious Diseases 45: 624-632.
18. Brodine SK, Starkey MJ, Shaffer RA, Ito SI, Tasker SA, et al. (2003) Diverse HIV-1 subtypes and clinical, laboratory and behavioral factors in a recently infected US military cohort. AIDS 17: 2521-2527.
19. Weintrob AC, Fieberg AM, Agan BK, Ganesan A, Crum-Cianflone NF, et al. (2008) Increasing age at HIV seroconversion from 18 to 40 years is associated with favorable virologic and immunologic responses to HAART. J Acquir Immune Defic Syndr 49: 40-47.
20. Centers for Disease Control and Prevention (1992) 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 41: Accessed Jan 4, 2008 at http:// www.cdc.gov/mmwr/preview/mmwrhtml/00018871.htm.
21. Vierling JM (2007) The immunology of hepatitis B. Clinics in Liver Disease 11: 727-759.
22. Rehermann B, Fowler P, Sidney J, Person J, Redeker A, et al. (1995) The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. Journal of Experimental Medicine 181: 1047-1058.
23. Day CL, Walker BD (2003) Progress in defining CD4 helper cell responses in chronic viral infections. Journal of Experimental Medicine 198: 1773-1777.
24. Sheng W, Kao J, Chen P, Huang L, Chang S, et al. (2007) Evolution of hepatitis B serological markers in HIV-infected patients receiving highly active antiretroviral therapy. Clinical Infectious Diseases 45: 1221-1229.
25. Piroth L, Binquet C, Vergne M, Minello A, Livry C, et al. (2002) The evolution of hepatitis B virus serological patterns and the clinical relevance of isolated antibodies to hepatitis B core antigen in HIV infected patients. Journal of Hepatology 36: 681-686.
26. Rouphael NG, Talati NJ, Rimland D (2007) Hepatitis B reverse seroconversion in HIV-positive patients: case series and review of the literature. AIDS 21: 771-774.
27. Piroth L, Sene D, Pol S, Goderel I, Lacombe K, et al. (2007) Epidemiology, diagnosis, and treatment of chronic hepatitis B in HIV-infected patients (EPIB 2005 STUDY). AIDS 21: 1323-1331.
28. Piroth L, Grappin M, Buisson M, Duong M, Portier H, et al. (2000) Hepatitis B virus seroconversion in HIV-HBV coinfected patients treated with highly active antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes 23: 356-357.
29. Hoff J, Bani-Sadr F, Gassin M, Raffi F (2001) Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens. Clinical Infectious Diseases 32: 963-969.
30. Lascar RM, Gilson RJ, Lopes AR, Bertoletti A, Maini MK (2003) Reconstitution of hepatitis B virus (HBV)-specific T cell responses with treatment of human immunodeficiency virus/HBV coinfection. Journal of Infectious Diseases 188: 1815-1819.
31. Lascar RM, Lopes AR, Gilson RJ, Dunn C, Johnstone R, et al. (2005) Effect of HIV infection and antiretroviral therapy on hepatitis B virus (HBV)-specific T cell responses in patients who have resolved HBV infection. Journal of Infectious Diseases 191: 1169-1179.
32. The Strategies for Management of Antiretroviral Therapy (SMART) Study Group (2006) CD4+ count-guided interruption of antiretroviral treatment. New England Journal of Medicine 355: 2283-2296.
33. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, et al. (2009) Effect of early versus deferred antiretroviral therapy for HIV on survival. New England Journal of Medicine 360: 1815-1826.